Effects of moxonidine and low-calorie diet: Cardiometabolic benefits from combination of both therapies


Lambert, Elisabeth A.; Sari, Carolina I.; Eikelis, Nina; Phillips, Sarah E.; Grima, Mariee; Straznicky, Nora E.; Dixon, John B.; Esler, Murray; Head, Geoffrey A.; Schlaich, Markus P.; Lambert, Gavin W.


Objective: Because sympathetic nervous system activity plays a detrimental role in metabolic and cardiovascular health, this study compared the effects of a centrally acting sympatholytic agent, the effects of a weight loss (WL) program using a low-calorie diet, and the effects of a combination of both. Methods: Young (18-30 years) male subjects with overweight (BMI > 25 kg/m 2 ) were allocated to a WL program (n=10), a moxonidine treatment course (M; n=10, 0.4 mg/d), a combination of both (WL+M; n=11), or to a control (C) group (n=6) for 6 months. Muscle sympathetic nerve activity (MSNA), endothelial function, renal function (Cockcroft-Gault formula), and the metabolic profile were assessed before and after intervention. Results: WL occurred in the WL and WL+M groups (-7.6±1.9 kg, P < 0.001 in both). MSNA and systolic blood pressure decreased similarly in the WL, M, and WL+M groups (by ∼10 bursts/min, P < 0.001, and by ∼9 mmHg, P < 0.05). All other parameters for the WL, C, and M groups remained unchanged. In the WL+M group, decreased total cholesterol (-0.78±0.23 mmol/L, P < 0.001), decreased low-density lipoprotein cholesterol (-0.49±0.16 mmol/L, P < 0.01), decreased insulin (-6.5±2.8 mmol/L, P < 0.05), and attenuated glomerular hyperfiltration (-19±5mL/min, P < 0.01) occurred. Conclusions: The combination of moxonidine with a WL program has beneficial effects on aspects of the metabolic profile and end organ damage in young males with overweight.

Publication year


Publication type

Journal article


Obesity, Vol. 25, no. 11 (Nov 2017), pp. 1894-1902






Copyright © 2017 The Obesity Society.